ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Trial Profile

ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Ublituximab (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ULTIMATE II
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 15 Sep 2017 According to a TG Therapeutics media release, global ULTIMATE I and II trials are being led by Dr. Lawrence Steinman.
    • 07 Sep 2017 Status changed from planning to recruiting.
    • 03 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top